Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction), empagliflozin reduced cardiovascular death or heart failure (HF) hospitalization and total HF hospitalizations, and slowed the progressive decline in kidney function in patients wi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Circulation
Hlavní autoři: Zannad, Faiez, Ferreira, João Pedro, Pocock, Stuart J., Zeller, Cordula, Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Hauske, Sibylle Jenny, Brueckmann, Martina, Pfarr, Egon, Schnee, Janet, Wanner, Christoph, Packer, Milton
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2020
Témata:
Original Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7834910/
https://ncbi.nlm.nih.gov/pubmed/33095032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.120.051685
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky